Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer

  • Technology appraisal guidance
  • TA1021
  • Published: 

History

Documents created during the development process.

Final draft guidance

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators